3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Ovarian Neoplasms
32
Breast Neoplasms
18
Neoplasms
9
Triple Negative Breast Neoplasms
8
Neoplasm Metastasis
7
Sarcoma
6
Prostatic Neoplasms
6
Fanconi Anemia, Complementation Group D1
6
Pancreatic Neoplasms
5
Endometrial Neoplasms
5
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Recurrence
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Fallopian Tube Neoplasms
4
Colorectal Neoplasms
4
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Mesothelioma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Central Nervous System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Advanced Solid Tumours
2
Advanced Solid Tumors
2
Wilms Tumor
1
Interventions
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
2
vistusertib
1
vandetanib
1
telomerase reverse transcriptase p572Y, human
1
spartalizumab
1
pembrolizumab
1
olaparib
1
durvalumab
1
capivasertib
1
Vinorelbine
1
Ramucirumab
1
Pemetrexed
1
Paclitaxel
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Carboplatin
1
Bevacizumab
1
AZD4547
1
AZD 8931
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Non-small Cell Lung Cancer Metastatic
×
olaparib
×
Clear all
NCT02117167
2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2
Completed
999 enrolled